Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Neurology Neurosurgery & Psychiatry

• Publication date

  2018-03-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/jnnp-2017-317493PMID 29602795
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Healthcare expenditure of multiple sclerosis patients in 2013: A nationwide study based on French health administrative databases

  2017cited by this paper
• Evaluating the safety of β-interferons in MS

  2017cited by this paper
• Infection-related health care utilization among people with and without multiple sclerosis

  2017cited by this paper
• Disease-modifying therapies and infectious risks in multiple sclerosis

  2016cited by this paper
• Fingolimod for relapsing-remitting multiple sclerosis.

  2016cited by this paper
• Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis

  2016cited by this paper
• The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review

  2015cited by this paper
• Corticosteroids for treating sepsis.

  2015cited by this paper
• Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.

  2015cited by this paper
• Type I interferon dysregulation and neurological disease

  2015cited by this paper
• Association between beta‐interferon exposure and hospital events in multiple sclerosis

  2014cited by this paper
• Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

  2014cited by this paper
• Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.

  2012cited by this paper
• Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

  2012cited by this paper
• Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort.

  2011cited by this paper
• Corticosteroids for pneumonia.

  2011cited by this paper
• Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

  2010cited by this paper
• A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

  2010cited by this paper
• The rising prevalence and changing age distribution of multiple sclerosis in Manitoba

  2010cited by this paper
• Infection as a comorbidity of COPD

  2010cited by this paper
• GLANCE

  2009cited by this paper
• 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

  2009cited by this paper
• Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis.

  2008cited by this paper
• Modeling Repeated Time-to-event Health Conditions with Discontinuous Risk Intervals

  2008cited by this paper
• Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.

  2008cited by this paper
• Risk factors for opportunistic infections in patients with inflammatory bowel disease.

  2008cited by this paper
• Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial

  2007cited by this paper
• Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

  2006cited by this paper
• A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

  2006cited by this paper
• Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus.

  2005cited by this paper
• Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.

  2005cited by this paper
• A controlled trial of natalizumab for relapsing multiple sclerosis.

  2003cited by this paper
• Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study.

  2002cited by this paper
• Corticosteroids or ACTH for acute exacerbations in multiple sclerosis.

  2000cited by this paper
• Semiparametric regression for the mean and rate functions of recurrent events

  2000cited by this paper
• Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

  1998cited by this paper
• Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

  1996cited by this paper
• Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

  1993cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper

• The relative risk of infection in people with multiple sclerosis using disease-modifying treatment: a systematic review of observational studies

  2025cites this paper
• A narrative review on the safety of glatiramer acetate in multiple sclerosis: focus on Europe

  2025cites this paper
• LPX-TI641, a Tim3/4 Agonist, Induces Long-Term Immune Tolerance in Multiple Sclerosis Models

  2025cites this paper
• Cervical Pathology Associated With Multiple Sclerosis Therapies

  2025cites this paper
• Serological screening and Vaccine Update in a cohort of Multiple Sclerosis Patients as a strategy to prevent infection reactivation during immunosuppressant therapy.

  2025cites this paper
• Rituximab for people with multiple sclerosis.

  2025cites this paper
• A disproportionality analysis of surgical site infections across multiple sclerosis disease modifying therapies

  2025cites this paper
• Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials

  2024cites this paper
• As time goes by: Treatment challenges in elderly people with multiple sclerosis.

  2024cites this paper
• Management of multiple sclerosis in older adults: review of current evidence and future perspectives

  2024cites this paper
• Coronavirus disease 2019 infection among working-aged people with multiple sclerosis and the impact of disease-modifying therapies

  2024influential citation
• Comorbilidades en la esclerosis múltiple y su influencia en la elección del tratamiento

  2024cites this paper
• Association of multiple sclerosis with stroke: A comprehensive review

  2024cites this paper
• Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis

  2024cites this paper
• Disease-modifying drugs, multiple sclerosis and infection-related healthcare use in British Columbia, Canada: a population-based study

  2024cites this paper
• Infection Risk Associated with High‐Efficacy Disease‐Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study

  2024cites this paper
• Features of the vaginal microbiota in women with relapsing-remitting multiple sclerosis

  2024cites this paper
• Ratio of lymphocyte to monocyte area under the curve as a novel predictive factor for severe infection in multiple sclerosis

  2023cites this paper
• Latin American consensus recommendations on the risk of infections in people with multiple sclerosis treated with disease modifying drugs.

  2023cites this paper
• Common comorbid and secondary conditions leading to hospitalization in multiple sclerosis patients in the United States.

  2023cites this paper
• Vaccination Coverage in Patients with Idiopathic Inflammatory Central Nervous System Demyelinating Diseases at Siriraj Hospital, A Single-center Experience

  2023cites this paper
• Disease-modifying therapies used to treat multiple sclerosis and the gut microbiome: a systematic review

  2023cites this paper
• Comparing the risk of serious infections in patients with and without MS: A German claims data analysis.

  2023cites this paper
• Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviors and access to disease-modifying therapies Multiple Sclerosis and Related Disorders

  2022cites this paper
• Multiple sclerosis and inflammatory bowel disease: A systematic review and meta‐analysis

  2022cites this paper
• Risk Factors for Infection and Health Impacts of the Coronavirus Disease 2019 (COVID-19) Pandemic in People With Autoimmune Diseases

  2022cites this paper
• Literatur

  2022cites this paper
• Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviors and access to disease-modifying therapies Multiple Sclerosis and Related Disorders

  2022cites this paper
• Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies

  2022cites this paper
• Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviors and access to disease-modifying therapies

  2022cites this paper
• Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviors and access to disease-modifying therapies

  2022cites this paper
• Low socioeconomic status was associated with a higher mortality risk in multiple sclerosis

  2022cites this paper
• Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.

  2022cites this paper
• Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviors and access to disease-modifying therapies

  2022cites this paper
• Predictors of Catching COVID-19 Infection during Pandemic Stage in Patients with Multiple Sclerosis (MS)

  2022cites this paper
• Outcomes of multiple sclerosis patients admitted with COVID-19 in a large veteran cohort

  2022cites this paper
• Melatonin and multiple sclerosis: antioxidant, anti-inflammatory and immunomodulator mechanism of action

  2022cites this paper
• Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?

  2022cites this paper
• Stroke risk in multiple sclerosis: a critical appraisal of the literature

  2022cites this paper
• Awareness of Patients With MS From Covid 19: A Cross-sectional Descriptive Study on the Second Wave of Coronavirus in Jahrom City

  2021cites this paper
• Ethical considerations in neurology during the COVID-19 pandemic

  2021cites this paper
• Genetic Diversity of SARS-CoV2 and Environmental Settings: Possible Association with Neurological Disorders

  2021cites this paper
• Treating MS After 50: the Role of Age in Therapeutic Decision-Making

  2021cites this paper
• Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment

  2021cites this paper
• Associations of DMT therapies with COVID-19 severity in multiple sclerosis

  2021cites this paper
• Considering patient age when treating multiple sclerosis across the adult lifespan

  2021cites this paper
• Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint

  2021cites this paper
• Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study

  2021influential citation
• SARS-CoV-2 Infection and Risk Management in Multiple Sclerosis

  2021cites this paper
• Review of the COVID-19 Risk in Multiple Sclerosis

  2021cites this paper
• Rituximab for people with multiple sclerosis.

  2021cites this paper
• RISK FACTORS FOR INFECTION AND HEALTH IMPACTS OF THE COVID-19 PANDEMIC IN PEOPLE WITH AUTOIMMUNE DISEASES

  2021cites this paper
• Attitude and Knowledge of Patients with Multiple Sclerosis (MS) About COVID-19 as Provided by Physicians

  2021cites this paper
• Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases.

  2021cites this paper
• Infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society.

  2021cites this paper
• Sepsis and multiple sclerosis: causative links and outcomes.

  2021cites this paper
• Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology

  2021cites this paper
• Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis

  2021cites this paper
• Multiple Sclerosis, COVID-19 and Vaccines: Making the Point

  2021influential citation
• COVID-19 and Autoimmune Demyelinating Diseases

  2021cites this paper
• Managing anxiety among multiple sclerosis patients during COVID-19 pandemic

  2021cites this paper
• Disease-modifying drugs for multiple sclerosis and subsequent health service use

  2021cites this paper
• Risk Factors for Infection and Health Impacts of the Coronavirus Disease 2019 (COVID-19) Pandemic in People With Autoimmune Diseases

  2021cites this paper
• COMORBIDITY AND PERSISTENCE OF DISEASE-MODIFYING THERAPY USE FOR RELAPSING REMITTING MULTIPLE SCLEROSIS by Natalie Elizabeth Parks Submitted in partial fulfilment of the requirements for the degree of Master of Science

  2020cites this paper
• Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg

  2020cites this paper
• Treatment of multiple sclerosis during the covid-19 pandemic

  2020cites this paper
• Inhibition of Human Neutrophil Functions In Vitro by Multiple Sclerosis Disease-Modifying Therapies

  2020cites this paper
• Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting

  2020cites this paper
• Immunology of COVID‐19 and disease‐modifying therapies: The good, the bad and the unknown

  2020cites this paper
• SARS-CoV-2 infection among patients with multiple sclerosis; A cross-sectional study

  2020cites this paper
• Chronic neurological diseases and COVID-19: Associations and considerations

  2020cites this paper
• Impact of the COVID-19 pandemic on the health care of >1,000 People living with multiple sclerosis: A cross-sectional study

  2020cites this paper
• WITHDRAWN: Incidence and mortality of COVID-19 in Iranian multiple sclerosis patients treated with disease-modifying therapies

  2020cites this paper
• Urinary tract infection in patients with multiple sclerosis: An overview.

  2020cites this paper
• Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis

  2020cites this paper
• Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity

  2020cites this paper
• COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable?

  2020cites this paper
• Trends and characteristics of infection-related hospital admissions in multiple sclerosis patients in Southwest Finland in 2009-2018.

  2020cites this paper
• Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach

  2020cites this paper
• The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic

  2020cites this paper
• Is multiple sclerosis a risk factor for infections?

  2020influential citation
• Infectious Complications of Biological Agents

  2020cites this paper
• Disease modifying therapies and infection risks in multiple sclerosis—a decision-making conundrum

  2020cites this paper
• Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic

  2020cites this paper
• What are the infectious risks with disease-modifying drugs for multiple sclerosis and how to reduce them? A review of literature.

  2020cites this paper
• Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.

  2020cites this paper
• COVID-19 will change MS care forever – No

  2020cites this paper
• COVID-19 prevention and multiple sclerosis management: The SAFE pathway for the post-peak

  2020cites this paper
• Establishment of a safety protocol for the administration of treatments in multiple sclerosis during the SARS-CoV-2 pandemic

  2020cites this paper
• B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran

  2020cites this paper
• Largest Study of Infection Rates in MS Confirms Higher Risk of Newer Agents

  2020cites this paper
• Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations

  2020cites this paper
• Comparison of brain atrophy in patients with multiple sclerosis treated with first‐ versus second‐generation disease modifying therapy without clinical relapse

  2020cites this paper
• Knowledge regarding COVID-19 pandemic in patients with multiple sclerosis (MS): A report from Iran

  2020cites this paper
• B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran

  2020cites this paper
• Case Report: Fingolimod and Cryptococcosis: Collision of Immunomodulation with Infectious Disease.

  2019cites this paper
• Assessing the risk of multiple sclerosis disease-modifying therapies

  2019cites this paper
• The 20-year history: Change of multiple sclerosis patient profile over 20 years.

  2019cites this paper
• Safety outcomes of disease-modifying therapies for relapsing-remitting multiple sclerosis: A network meta-analysis.

  2019cites this paper
• Drug-use patterns and severe adverse events with disease-modifying drugs in patients with multiple sclerosis: a cohort study based on German claims data

  2019cites this paper